About Viaqua
ViAqua Therapeutics was established in September 2014 to address the growing need for effective, affordable health management of diseases in aquaculture. To date, ViAqua has received investments from The Trendlines Group , Nutreco, VisVires New Protein and the Technion–Israel Institute of Technology, with support from the Israel Innovation Authority.
​
Achievements
​
Q1 2018: Proof-of-concept for oral delivery of first product
Q3 2018: ViAqua receives investment from Nutreco and VisVires New Protein
Q3 2018: Signed joint development agreement with Skretting SA (Nutreco’s aquaculture division) for first product, including distribution and marketing by Skretting
2019: Preparing for high-volume manufacturing and improved product efficacy
ViAqua’s co-founders have Ph.D.s in molecular biology and marine biology, respectively. The Company’s management bring a broad range of business development, technology development, management, and industrial biotech experience.
Current Partners:
Shai Ufaz, Ph.D.
CEO & Co-Founder
Molecular biology
Molecular biologist; experience in biotechnology, genetic engineering, protein expression; Project manager, Protalix Biotherapeutics, TransAlgae; Ph.D., plant genetics
Shai Einbinder, Ph.D.
Co-Founder
Marine biology
Marine biologist; experience in product development, management; VP Development & Projects, TransAlgae; CEO, Aurora-V; Ph.D., marine biology
Prof. Avi Schroeder
Scientific Advisor
Drug delivery
Extensive development in fields of RNA and protein delivery and nanotechnology; Asst. Prof. of Chemical Engineering, Technion-Israel Institute of Technology; postdoctoral fellow with Prof. Robert Langer, MIT
Dganit Vered
Chairperson & VP BD
Senior Corporate & R&D management
Over 20 years’ experience in senior executive positions in Intel, Perrigo and Hazera, in R&D, Engineering and Operations. Professional experience includes former head of R&D in vegetable seeds, VP R&D in the Pharma API industry, and various engineering and operations positions in the Silicon wafer top niche industry.
Ami Schlesinger, PhD, MBA
Executive VP Product & Innovation
Marine biology
Marine zoologist with extensive business experience; previously, Researcher at TransAlgae, Director of R&D at Nanocyte, and Executive Chairman of Business at Ma'agan Michael; led several firms in senior executive positions spanning diverse fields, including agriculture, aquaculture, desalination, cleantech, energy, trading, precision technology, and plastics.